株式会社AIメディカルサービス

Market position

The company positions itself as a leading player in endoscopy AI, citing more than 50 published AI papers, world-first publications on AI for H. pylori discrimination (2017) and gastric cancer detection (2018), and demonstration in April 2020 that its gastric cancer detection AI significantly exceeded endoscopy specialists in sensitivity. Investor commentary at the Series B described it as holding one of Japan's largest accumulations of endoscopic images and paper data in a market with few entrants.

Compared with much of the field, which the company says concentrates on colorectal polyps and still images, it targeted early gastric cancer as its first product and developed video-capable AI covering detection, discrimination and lesion-extent display. It also cites joint research with more than 100 medical institutions — including the Cancer Institute Hospital of JFCR, Osaka International Cancer Institute, the University of Tokyo Hospital and Keio University Hospital — as a data-supply base.

Technology

The products apply deep learning to endoscopic images to detect and characterize lesions. Capabilities described include detection (lesion pick-up), discrimination of lesion state, and display of lesion extent, with work spanning still images and video, and covering gastric cancer, esophageal cancer, colorectal lesions, ulcerative colitis state assessment and capsule endoscopy. Products under development were confirmed compliant with IEC 62304 and IEC 62366-1 in July 2021.

Go-to-market

Products reach the market through Japanese regulatory approval followed by domestic sales from March 2024, overseas device registration in Singapore and Thailand, and distribution/alliance arrangements; Ryoyo Electro supports end-to-end introduction of the company's AI endoscopic image diagnosis support software into clinical settings, and a March 2024 business alliance with LPIXEL was reported. Joint research agreements with domestic and overseas hospitals support clinical validation, and the company recruits directly through its own careers site and internship program.

Endoscopists and gastroenterology departments at hospitals and clinics, including screening programs performing gastric endoscopy and secondary image reading.

Geography

Headquarters in Toshima-ku, Tokyo, with a US entity at the Chrysler Building, 405 Lexington Ave., New York (US subsidiary first established in Silicon Valley in January 2022; New York office opened January 2023) and a Singapore entity at Westgate Tower, 1 Gateway Drive. Products have been registered in Singapore (February 2024) and approved in Thailand (June 2025).

History

After its September 2017 founding, the company published what it describes as world-first papers on AI detection of gastric cancer in still images (January 2018), esophageal cancer (January 2019) and gastric cancer in video (March 2019). It raised a Series A in August 2018 and a Series B in October 2019. In November 2019 an endoscopy AI system under development received FDA Breakthrough Device designation. Awards followed in 2020 (EY Innovative Startup 2020, the 5th JEITA Venture Award, CEATEC AWARD 2020 Co-Creation PARK grand prize), and the office moved to Hareza Tower in August 2020. In 2021 the company signed a joint research agreement with National University Hospital, Singapore, launched the gastroAI Online research media, was selected as a World Economic Forum Technology Pioneer and as a J-Startup company, and applied for regulatory approval of its first domestic product. A US subsidiary was established in Silicon Valley in January 2022, a Series C closed in May 2022, a Singapore subsidiary followed in July 2022 and a New York office in January 2023. Manufacturing and marketing approval for gastroAI model-G was obtained in December 2023, with device registration completed in Singapore in February 2024, approval of gastroAI model-G2 in December 2024, Thai medical device approval in June 2025 and approval of gastroAI model-G3 in May 2026.